Association between the use of β-adrenergic receptor agents and the development of venous leg ulcers

Archives of Dermatology

Volumn 143, Issue 10, 2007, Pages 1275-1280

  Margolis, David J ^a,d   Hoffstad, Ole ^a   Isseroff, R Rivkah ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; LEG ULCER; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; VARICOSE ULCER;

EID: 35348983964     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.10.1275     Document Type: Article

References (27)

1. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006;126(9):1948-1965.
2. Mahrle G, Orfanos CE. Lack of beta-adrenergic stimulation of membrane bound adenyl cyclase in psoriasis as compared to normal epidermis [author's transl] [in German]. Arch Dermatol Res. 1975;253(2):195-202.
3. Venning GR. Identification of adverse reactions to new drugs. Br Med J (Clin Res Ed). 1983;286(6361):289-292.
4. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis: a review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol. 1988;19(5, pt 1):837-841.
5. O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5(5):426-432.
6. Pullar CE, Grahn JC, Liu W. Beta2-adrenergic receptor activation delays wound healing. FASEB J. 2006;20(1):76-86.
7. Pullar CE, Chen J, Isseroff RR. PP2A activation by beta2-adrenergic receptor agonists: novel regulatory mechanism of keratinocyte migration. J Biol Chem. 2003;278(25):22555-22562.
8. Chen J, Hoffman BB, Isseroff RR. Beta-adrenergic receptor activation inhibits keratinocyte migration via a cyclic adenosine monophosphate-independent mechanism. J Invest Dermatol. 2002;119(6):1261-1268.
9. Pullar CE, Rizzo A, Isseroff RR. Beta-adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. J Biol Chem. 2006;281(30):21225-21235.
10. Sivamani RK, Pullar CE, Griffths B, Isseroff RR. Beta-2-adrenergic receptor blockade accelerates burn wound healing. J Invest Dermatol. 2006;126:59.
11. Pullar CE, Isseroff RR. The beta 2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms. J Cell Sci. 2006;119(pt 3):592-602.
12. Margolis DJ, Knauss J, Bilker W. Medical conditions associated with venous leg ulcers in an outpatient. Br J Dermatol. 2004;150(2):267-273.
13. Margolis DJ, Bilker W, Santanna J, Baumgartern M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol. 2002;46(3):381-386.
14. Kirsner RS, Pardes JB, Eaglstein WH, Falanga V. The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol. 1993;28(4):623-627.
15. Margolis DJ, Knauss J, Bilker W. Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers. Lancet. 2002;359(9307):675-677.
16. Margolis DJ, Bartus C, Hofstad O, Malay S, Berlin JA. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen. 2005;13(6):531-536.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
18. Skene AI, Smith JM, Dore CJ, Charlett A, Lewis JD. Venous leg ulcers: a prognostic index to predict time to healing. BMJ. 1992;305(6862):1119- 1121.
19. Margolis DJ, Berlin JA, Strom BL. Risk factors associated with the failure of a venous leg ulcer to heal. Arch Dermatol. 1999;135(8):920-926.
20. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381-411.
21. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-944.
22. Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005;289(2):H947-H959.
23. Smith PC. The causes of skin damage and leg ulceration in chronic venous disease. Int J Low Extrem Wounds. 2006;5(3):160-168.
24. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(suppl 1):S11-S19.
25. Trent JT, Falabella A, Eaglstein WH, Kirsner RS. Venous ulcers: pathophysiology and treatment options. Ostomy Wound Manage. 2005;51(5):38-54.
26. Miyamoto M, Tomaki M, Lotvall J, Linden A. Beta-adrenoceptor stimulation and neutrophil accumulation in mouse airways. Eur Respir J. 2004;24(2):231-237.
27. Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome. Crit Care. 2004;8(1):25-32.